ReviewFrontiers in microbiology2016
Veterinary Medicine Needs New Green Antimicrobial Drugs.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Species Diversity and Antimicrobial Susceptibility of Staphylococci Colonising Healthy Dogs-A Single-Centre Cross-Sectional Study in Bulgaria.Antibiotics (Basel, Switzerland) · 2026Article
- Effects of environmentally relevant ibuprofen and valproic acid exposure on zebrafish behavior.Biomolecules & biomedicine · 2026Article
- High prevalence of antimicrobial residues in broiler meat in Bangladesh, India and Vietnam.NPJ science of food · 2026Article
- Article
- Antibiotic Resistance Crisis: From Bacterial Bioprospecting to Artificial Intelligence.Environmental microbiology reports · 2025Review
- Antimicrobial Resistance in European Companion Animals Practice: A One Health Approach.Animals : an open access journal from MDPI · 2025Review
- Dietary Galacto-Oligosaccharides Enhance Growth Performance and Modulate Gut Microbiota in Weaned Piglets: A Sustainable Alternative to Antibiotics.Animals : an open access journal from MDPI · 2025Article
- Causal Association Between the Mucosal and Luminal Microbiotas from the Gastrointestinal Tract of Weaned Piglets Using Bayesian Network.Microorganisms · 2025Article
- Selection for florfenicol resistance at sub-MIC concentrations in Pasteurella multocida.PloS one · 2025Article
- Review
- Pharmacokinetic/pharmacodynamic integration of amphenmulin: a novel pleuromutilin derivative againstMicrobiology spectrum · 2024Article
- Exploring the additive effect of Ampelopsis grossedentata flavonoids and Tween 80 on feeding Nubian goats.Frontiers in veterinary science · 2024Article
- The Use of Antibiotics and Antimicrobial Resistance in Veterinary Medicine, a Complex Phenomenon: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Compound organic acid could improve the growth performance, immunity and antioxidant properties, and intestinal health by altering the microbiota profile of weaned piglets.Journal of animal science · 2023Article
- Intestinal Exposure to Ceftiofur and Cefquinome after Intramuscular Treatment and the Impact of Ceftiofur on the Pig Fecal Microbiome and Resistome.Antibiotics (Basel, Switzerland) · 2022Article
- Current perspective on veterinary drug and chemical residues in food of animal origin.Environmental science and pollution research international · 2022Review
- Essential oils and their nanoemulsions as green alternatives to antibiotics in poultry nutrition: a comprehensive review.Poultry science · 2022Review
- Rational Pharmacotherapy in Infectious Diseases: Issues Related to Drug Residues in Edible Animal Tissues.Animals : an open access journal from MDPI · 2021Review
- Ferulic acid inhibits LPS-induced apoptosis in bovine mammary epithelial cells by regulating the NF-κB and Nrf2 signalling pathways to restore mitochondrial dynamics and ROS generation.Veterinary research · 2021Article
- New Trimethoprim-Like Molecules: Bacteriological Evaluation and Insights into Their Action.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given that: (1) the worldwide consumption of antimicrobial drugs (AMDs) used in food-producing animals will increase over the coming decades; (2) the prudent use of AMDs will not suffice to stem the rise in human antimicrobial resistance (AMR) of animal origin; (3) alternatives to AMD use are not available or not implementable, there is an urgent need to develop novel AMDs for food-producing animals. This is not for animal health reasons, but to break the link between human and animal resistomes. In this review we establish the feasibility of developing for veterinary medicine new AMDs, termed "green antibiotics," having minimal ecological impact on the animal commensal and environmental microbiomes. We first explain why animal and human commensal microbiota comprise a "turnstile" exchange, between the human and animal resistomes. We then outline the ideal physico-chemical, pharmacokinetic, and pharmacodynamic properties of a veterinary green antibiotic and conclude that they can be developed through a rational screening of currently used AMD classes. The ideal drug will be hydrophilic, of relatively low potency, slow clearance and small volume of distribution. It should be eliminated principally by the kidney as inactive metabolite(s). For oral administration, bioavailability can be enhanced by developing lipophilic pro-drugs. For parenteral administration, slow-release formulations of existing eco-friendly AMDs with a short elimination half-life can be developed. These new eco-friendly veterinary AMDs can be developed from currently used drug classes to provide alternative agents to those currently used in veterinary medicine and mitigate animal contributions to the human AMR problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.